AR038144A1 - Agonistas del receptor 2 del factor liberador de la corticotropina - Google Patents

Agonistas del receptor 2 del factor liberador de la corticotropina

Info

Publication number
AR038144A1
AR038144A1 ARP030100101A ARP030100101A AR038144A1 AR 038144 A1 AR038144 A1 AR 038144A1 AR P030100101 A ARP030100101 A AR P030100101A AR P030100101 A ARP030100101 A AR P030100101A AR 038144 A1 AR038144 A1 AR 038144A1
Authority
AR
Argentina
Prior art keywords
peptide
corticotropine
liberating
agonists
crf2r
Prior art date
Application number
ARP030100101A
Other languages
English (en)
Inventor
Robert Joseph Isfort
Wieslaw Adam Mazur
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of AR038144A1 publication Critical patent/AR038144A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Un péptido no nativo que comprende la secuencia: X2X3PSLSIDX10PX12X13X14LLRTLLELEKTQSQRERAEQNAX36IFAX40V en donde X2 es D o no existe; X3 es N o no existe; X10 se selecciona de L y V; X12 se selecciona de L, y F; X13 se selecciona de L, F, y Y; X14 hasta X35 comprenden las secuencias que se describen en la Memoria; X36 se selecciona de R, H, y Q; X40 se selecciona de H y R y variantes de éstos. Dicho péptido se selecciona de entre las secuencias N°: 324, 328, 331, 333, 334,341, 384, 385, 386, y 387 tal como se describen en la Memoria. Uso para preparar una composición farmacéutica útil para evitarlo o tratar un trastorno modulado por CRF2R que comprende una cantidad segura y eficaz de dicho péptido. Ácido nucleico aislado que codifica dicho péptido. Anticuerpo aislado específico para dicho péptido. Composición farmacéutica que comprende una cantidad segura y eficaz de dicho péptido y un portador farmacéuticamente aceptable. Conjunto o Kit para evitar o tratar un trastorno modulado por CRF2R que comprende dicho péptido en una forma de dosis unitaria e instrucciones de uso.
ARP030100101A 2002-01-16 2003-01-15 Agonistas del receptor 2 del factor liberador de la corticotropina AR038144A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US34911702P 2002-01-16 2002-01-16
US37633702P 2002-04-29 2002-04-29
US38889502P 2002-06-14 2002-06-14
US41198802P 2002-09-19 2002-09-19

Publications (1)

Publication Number Publication Date
AR038144A1 true AR038144A1 (es) 2004-12-29

Family

ID=27617822

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP030100099A AR038142A1 (es) 2002-01-16 2003-01-15 Agonistas del receptor 2 del factor liberador de la corticotropina
ARP030100100A AR038143A1 (es) 2002-01-16 2003-01-15 Agonistas del receptor 2 del factor liberador de la corticotropina
ARP030100101A AR038144A1 (es) 2002-01-16 2003-01-15 Agonistas del receptor 2 del factor liberador de la corticotropina

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ARP030100099A AR038142A1 (es) 2002-01-16 2003-01-15 Agonistas del receptor 2 del factor liberador de la corticotropina
ARP030100100A AR038143A1 (es) 2002-01-16 2003-01-15 Agonistas del receptor 2 del factor liberador de la corticotropina

Country Status (30)

Country Link
US (7) US7192923B2 (es)
EP (4) EP1724283B1 (es)
JP (3) JP4508649B2 (es)
KR (3) KR100735586B1 (es)
CN (3) CN100475844C (es)
AR (3) AR038142A1 (es)
AT (4) ATE398632T1 (es)
AU (2) AU2003205197B2 (es)
BR (3) BR0306878A (es)
CA (3) CA2470731C (es)
CY (1) CY1106133T1 (es)
DE (4) DE60318547T2 (es)
DK (2) DK1465923T3 (es)
ES (4) ES2299701T3 (es)
HK (1) HK1078095A1 (es)
IL (5) IL162530A0 (es)
MA (3) MA27592A1 (es)
MX (3) MXPA04006883A (es)
MY (1) MY140306A (es)
NO (3) NO20043371L (es)
NZ (3) NZ533599A (es)
PE (3) PE20030747A1 (es)
PL (3) PL373529A1 (es)
PT (2) PT1465923E (es)
RU (1) RU2294333C2 (es)
SA (3) SA03230565B1 (es)
SI (1) SI1465921T1 (es)
TW (3) TW200302278A (es)
WO (3) WO2003062269A2 (es)
ZA (1) ZA200404995B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2427490A1 (en) * 2000-09-22 2002-03-28 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Methods for improving the antagonistic/agonistic properties of peptidic antagonists/agonists of the corticotropin-releasing factor receptor (crfr)
US7192923B2 (en) * 2002-01-16 2007-03-20 The Procter & Gamble Company Corticotropin releasing factor 2 receptor agonists
WO2005103690A2 (en) * 2004-04-24 2005-11-03 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with corticotropin releasing hormone receptor 2 (crhr2)
WO2006110413A2 (en) * 2005-03-30 2006-10-19 Novartis Vaccines And Diagnostics Inc. Haemophilus influenzae type b
US7815905B2 (en) 2006-01-27 2010-10-19 Research Development Foundation Methods of increasing insulin sensitivity or decreasing insulin secretion by administering corticotropin releasing factor receptor-2 inhibitors
JP2010538993A (ja) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト ペプチドＰｒｏ−Ｇｌｙ−Ｔｈｒ−Ｃｙｓ−Ｇｌｕ−Ｉｌｅ−Ｃｙｓ−Ａｌａ−Ｔｙｒ−Ａｌａ−Ａｌａ−Ｃｙｓ−Ｔｈｒ−Ｇｌｙ−Ｃｙｓの治療剤としての使用
WO2009046874A1 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Therapeutic combination of trh-potentiating peptide and stresscopin
WO2009040027A1 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of the peptide stresscopin as a therapeutic agent
KR20110091720A (ko) * 2008-11-04 2011-08-12 얀센 파마슈티카 엔.브이. Ｃｒｈｒ2 펩티드 작용제 및 이의 용도
EP2206726A1 (en) * 2009-01-08 2010-07-14 Universite Joseph Fourier Non-invasive tools for detecting vulnerable atherosclerotic plaques
WO2011057027A2 (en) * 2009-11-04 2011-05-12 Janssen Pharmaceutica Nv Method for treating heart failure with stresscopin-like peptides
WO2013063046A1 (en) 2011-10-24 2013-05-02 Research Development Foundation Methods for increasing insulin secretion by co-stimulation of corticotropin-releasing factor receptors
PL2814513T3 (pl) * 2012-02-14 2018-06-29 The Regents Of The University Of California Układowe dostarczanie i regulowana ekspresja genów parakrynnych w chorobach sercowo-naczyniowych i innych stanach
JOP20170153A1 (ar) * 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
WO2018075973A2 (en) * 2016-10-20 2018-04-26 Cortene Inc. Methods of treating diseases resulting from a maladapted stress response
CN110755434B (zh) * 2018-07-27 2022-03-15 中国医学科学院药物研究所 化合物palosuran防治骨骼肌萎缩等疾病的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5235036A (en) * 1991-05-31 1993-08-10 The Salk Institute For Biological Studies Crf analogs
EP0860501A3 (en) 1994-06-14 1999-05-19 Neurocrine Biosciences, Inc. Corticotropin-releasing factor2 receptors
US5786203A (en) * 1994-06-14 1998-07-28 Neurocrine Biosciences, Inc. Isolated nucleic acid encoding corticotropin-releasing factor2 receptors
US5663292A (en) * 1994-12-12 1997-09-02 The Salk Institute For Biological Studies Cyclic CRF analogs
US5824771A (en) 1994-12-12 1998-10-20 The Salk Institute For Biological Studies Cyclic CRF agonists
US5660824A (en) 1995-05-24 1997-08-26 Grabstein; Kenneth H. Muscle trophic factor
WO1997000063A2 (en) 1995-06-13 1997-01-03 The Salk Institute For Biological Studies Urocortin peptides
US5869450A (en) 1996-03-06 1999-02-09 The Regents Of The University Of California Anti-inflammatory compositions and method with corticotropin-releasing factor analogs
KR100879232B1 (ko) 2000-08-04 2009-01-20 리서치 디벨럽먼트 파운데이션 우로코르틴 단백질 및 이를 포함하는 약제학적 조성물
US20020082409A1 (en) 2000-10-26 2002-06-27 Hsu Sheau Yu Stresscopins and their uses
US6670140B2 (en) * 2001-03-06 2003-12-30 The Procter & Gamble Company Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
US7192923B2 (en) * 2002-01-16 2007-03-20 The Procter & Gamble Company Corticotropin releasing factor 2 receptor agonists

Also Published As

Publication number Publication date
NO20043371L (no) 2004-10-06
IL162530A0 (en) 2005-11-20
MXPA04006883A (es) 2004-12-06
PL373529A1 (en) 2005-09-05
CA2470743A1 (en) 2003-07-31
EP1465923B1 (en) 2007-05-16
BR0306878A (pt) 2004-10-26
MA27592A1 (fr) 2005-11-01
BR0306826A (pt) 2005-09-06
KR20040082392A (ko) 2004-09-24
KR20040082389A (ko) 2004-09-24
IL162431A0 (en) 2005-11-20
WO2003062269A2 (en) 2003-07-31
CA2470656A1 (en) 2003-07-31
NZ533598A (en) 2007-03-30
EP1724283B1 (en) 2008-06-18
TW200302278A (en) 2003-08-01
BR0306838A (pt) 2005-04-05
CA2470656C (en) 2011-06-28
US20100197579A1 (en) 2010-08-05
TWI300442B (en) 2008-09-01
EP1465922B1 (en) 2008-01-09
KR100758857B1 (ko) 2007-09-14
MY140306A (en) 2009-12-31
CN1617885A (zh) 2005-05-18
WO2003062269A3 (en) 2003-11-06
DE60321730D1 (de) 2008-07-31
DE60318547D1 (de) 2008-02-21
DE60307044T2 (de) 2007-02-15
US7192924B2 (en) 2007-03-20
WO2003062277A1 (en) 2003-07-31
TW200302276A (en) 2003-08-01
EP1465921B1 (en) 2006-07-26
DE60313845D1 (de) 2007-06-28
PL371364A1 (en) 2005-06-13
AR038142A1 (es) 2004-12-29
TW200302277A (en) 2003-08-01
US20060025339A1 (en) 2006-02-02
DE60307044D1 (de) 2006-09-07
CN1617887A (zh) 2005-05-18
CN100475844C (zh) 2009-04-08
PT1465923E (pt) 2007-08-06
SI1465921T1 (sl) 2006-10-31
NO20043366L (no) 2004-10-06
ES2309909T3 (es) 2008-12-16
CN100391972C (zh) 2008-06-04
CA2470743C (en) 2011-12-13
NZ533599A (en) 2007-03-30
ATE383372T1 (de) 2008-01-15
AR038143A1 (es) 2004-12-29
US20030148957A1 (en) 2003-08-07
US6936585B2 (en) 2005-08-30
ATE334147T1 (de) 2006-08-15
AU2003205197B2 (en) 2006-03-02
EP1724283A3 (en) 2007-04-11
ATE362488T1 (de) 2007-06-15
SA03230564B1 (ar) 2006-10-31
JP2005521387A (ja) 2005-07-21
WO2003062268A3 (en) 2003-11-27
CA2470731A1 (en) 2003-07-31
US7608701B2 (en) 2009-10-27
CN1617886A (zh) 2005-05-18
PT1465921E (pt) 2006-12-29
MA27590A1 (fr) 2005-11-01
KR100758858B1 (ko) 2007-09-14
JP4508648B2 (ja) 2010-07-21
ATE398632T1 (de) 2008-07-15
PE20030974A1 (es) 2003-12-26
US20090124793A1 (en) 2009-05-14
NO20043396L (no) 2004-10-06
US7897731B2 (en) 2011-03-01
US20030148956A1 (en) 2003-08-07
ES2287484T3 (es) 2007-12-16
RU2004124847A (ru) 2005-04-20
NZ533600A (en) 2007-02-23
US20030148958A1 (en) 2003-08-07
MA27591A1 (fr) 2005-11-01
CA2470731C (en) 2011-06-21
US20080004435A1 (en) 2008-01-03
MXPA04006885A (es) 2004-12-06
PE20030849A1 (es) 2003-12-01
US7462597B2 (en) 2008-12-09
ES2269976T3 (es) 2007-04-01
SA03230565A (ar) 2005-12-03
DE60318547T2 (de) 2008-12-24
PE20030747A1 (es) 2003-10-23
IL162529A0 (en) 2005-11-20
RU2294333C2 (ru) 2007-02-27
US7632933B2 (en) 2009-12-15
KR20040082390A (ko) 2004-09-24
SA03230564A (ar) 2005-12-03
AU2003237419B2 (en) 2006-04-13
WO2003062268A2 (en) 2003-07-31
DK1465923T3 (da) 2007-07-02
KR100735586B1 (ko) 2007-07-04
IL197774A0 (en) 2009-12-24
IL196384A0 (en) 2011-07-31
PL373139A1 (en) 2005-08-22
EP1465922A2 (en) 2004-10-13
EP1465921A2 (en) 2004-10-13
CY1106133T1 (el) 2011-06-08
ZA200404995B (en) 2005-06-29
SA03230565B1 (ar) 2006-10-31
DK1465921T3 (da) 2006-11-27
US7192923B2 (en) 2007-03-20
JP2005525101A (ja) 2005-08-25
ES2299701T3 (es) 2008-06-01
HK1078095A1 (en) 2006-03-03
EP1465923A1 (en) 2004-10-13
MXPA04006884A (es) 2004-12-06
JP4489434B2 (ja) 2010-06-23
DE60313845T2 (de) 2008-01-31
JP2005522191A (ja) 2005-07-28
JP4508649B2 (ja) 2010-07-21
EP1724283A2 (en) 2006-11-22

Similar Documents

Publication Publication Date Title
AR038144A1 (es) Agonistas del receptor 2 del factor liberador de la corticotropina
MX2022006672A (es) Compuestos bifuncionales para la degradacion de btk a traves de la via de proteosomas de ubiquitina.
JOP20220130A1 (ar) مجموعات تترا هيدروفيوران بها استبدال في صورة عوامل تعديل لقنوات الصوديوم
TR200201874T2 (tr) Proteaz inhibitörleri olarak yeni bileşikler ve bileşimler.
DK1317419T3 (da) Cyanophenoxycarboxylsyre-forbindelser og sammensætninger til at levere aktive midler
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
AR072442A1 (es) Metodo para la terapia del cancer, uso, kit
MXPA04009163A (es) Nuevos compuestos.
TW200510375A (en) New compounds
RU2013121788A (ru) Ингибиторы репликации вич
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
AR059324A2 (es) Una forma solida de dosificacion oral
BRPI0414867A (pt) pirazolopiridinas e seus análogos
EA200702093A1 (ru) Антитела-миметики glp-1 человека, композиции, способы и их применение
IS6750A (is) Samrunnin heterósýklísk súkkínímíð efnasambönd oghliðstæður þeirra, stillar fyrir starfsemi kjarnahormónaviðtaka
EA200101005A1 (ru) Высокоэффективные композиции, содержащие дигидроэрготамин
EA200701131A1 (ru) Гелеобразная препаративная форма капсаициноида и способы её применения
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
CO5580767A2 (es) Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas y procedimientos para su uso
NO20054371L (no) Somatostatin-dopamin kimaere analoger
MX2021002981A (es) Pirrolinas fusionadas que actuan como inhibidores de la proteasa 30 especifica de la ubiquitina (usp30).
CL2008003939A1 (es) Uso de escitalopram o una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento de ansiedad social (divisional de la solicitud 1799-00).
PE20150161A1 (es) Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple
ATE499939T1 (de) Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend
SE0002729D0 (sv) Novel compound form

Legal Events

Date Code Title Description
FB Suspension of granting procedure